AB201 DEVELOPMENT PROGRAM FOR TREATMENT OF COVID-19ARCA BIOPHARMA ANNOUNCES AB201 DEVELOPMENT PROGRAM FOR TREATMENT OF COVID-19 ASSOCIATED COAGULOPATHY arcabio.com The Westminster, Colorado-based company said it plans to evaluate AB201, a selective inhibitor of tissue factor, as a potential treatment for COVID-19-associated coagulopathy and the related inflammatory response. Coagulopathy is among the most serious adverse effects seen in COVID-19 patients, according to Arca. The company said its AB201 has been previously tested through Phase 2 trials in more than 700 patients for other indications and has generated substantial safety data. A Phase 2b/3 protocol is being developed in collaboration with the Colorado Prevention Center, the research wing of the University of Colorado, for hospitalized COVID-19 patients with elevated D-dimer levels, the company said. www.benzinga.com www.globenewswire.com by AlenCiken4
What if this is bullish price action?Maybe it's too early to tell but I like itLongby dobisaUpdated 2
$ABIO Breakout in ARCA BIO-PHARM 80% UPSIDE POTENTIAL Be on the watch-out for massive continuation today after great results yesterday. Already up 19% premarket. RESULTS TRANSCRIPT “In the first part of this year, we continued to make progress on our lead development program Gencaro, achieving an agreement with the FDA on our Special Protocol Assessment for the PRECISION-AF Phase 3 clinical trial evaluating Gencaro as potentially the first genetically-targeted treatment for atrial fibrillation,” commented Dr. Michael Bristow, ARCA’s President and Chief Executive Officer. “Importantly, the GENETIC-AF Phase 2B clinical trial results, which are guiding our Phase 3 development, were accepted and published in JACC: Heart Failure.” Company Description ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, GencaroTM is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indicationsLongby DEXWireNews7
ARCA Biopharma Announces FDA Agreement for a Single Phase 3today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 clinical trial, PRECISION-AF, to assess the safety and efficacy of GencaroTM (bucindolol hydrochloride) as a genetically-targeted treatment for atrial fibrillation (AF) in patients with a specific type of heart failure (HF). finance.yahoo.com by AlenCiken0
ABIO Where From HereBiggest gapper today #ABIO $ABIO, fell right away at market open. Looks to be setting up some possible support, ill watch it tomorrow and the next few days to see if we can break back above the median. You can visit my youtube and watch my full video recap, link in the description!by TradeWithTyler1
What I like about ABIO as a swing playWhat I like about ABIO as a swing play: 1. All moving avgs in alignment 2. Even with today's bearish candle, we still have a hook 3. We are still possibly coming out of oversold 4. The MACD is about to give a buy signal 5. They had positive news Feb 27 6. Traders love filling the gap from Feb 23 7. Needs to keep having higher highs and higher lows. 8. Needs to stay above RSI 30 9. Needs a significant hook continuation on 8ma. 10. Low short interest 11. At best a medium risk swing play. If you like my ideas, consider subscribing to my free overnight hold alerts discord.gg Longby Round_Table_Trade_Team_LLC4